Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Abstract: A process for separating components of a waste stream. In one embodiment, the process includes providing shredded material in a form of particles each having a size of less than 2 inches. The particles of shredded material are separated based on size into a plurality of streams. Each of the plurality of streams is separated, based on density, into a first substream of greater density and a second sub stream of lesser density. Brittle components of each first substream are pulverized, leaving metallic components in sheet form. Metallic components are separated from the first substream after the pulverizing. The process can be utilized to recover metals from automobile shredder residue, such as copper, aluminum, and precious metals.

Abstract: A deployable conscious or unconscious person-in-the-water rescue apparatus that can be manually or automatically deployed multiple and consecutive times to assist both a rescuer and a person-in-the-water by providing a tethered net that self-deploys in the water and supports the person-in-the-water while being pulled to safety.

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

Abstract: The present application relates to compositions and methods for modulating expression of Family with Sequence Similarity 13 Member A (FAM13A) protein. In particular, the present application relates to nucleic acid-based therapeutics for reducing FAM13A gene expression via RNA interference and methods of using such nucleic acid-based therapeutics to reduce abdominal adiposity, reduce body weight, reduce fat mass, improve metabolic parameters including insulin resistance and non-alcoholic steatohepatitis (NASH), and reduce risk of myocardial infarction.

Abstract: A process for separating components of a waste stream. In one embodiment, the process includes providing shredded material in a form of particles each having a size of less than 2 inches. The particles of shredded material are separated based on size into a plurality of streams. Each of the plurality of streams is separated, based on density, into a first substream of greater density and a second sub stream of lesser density. Brittle components of each first substream are pulverized, leaving metallic components in sheet form. Metallic components are separated from the first substream after the pulverizing. The process can be utilized to recover metals from automobile shredder residue, such as copper, aluminum, and precious metals.

Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Abstract: A deployable conscious or unconscious person-in-the-water rescue apparatus that can be manually or automatically deployed multiple and consecutive times to assist both a rescuer and a person-in-the-water by providing a tethered net that self-deploys in the water and supports the person-in-the-water while being pulled to safety.

Abstract: A rack display comprising a base having a front panel with a plurality of horizontal and vertical slots included thereon; left and right side panels extending from sides of the front panel; a back panel extending between the left and right side panels; and one or more shelf members including horizontal and vertical tabs. The shelf members are secured to the base by inserting the vertical and horizontal tabs within the vertical and horizontal slots respectively. The rack display is erected from a knockdown configuration by securing the shelf members to the front panel of the base via insertion of the horizontal and vertical tabs within the horizontal and vertical slots respectively.

Abstract: A corrugated box container with a main component including a base section and first and second side sections. The box container additionally includes first and second side support components associated with the first and second side sections for reinforcing the first and second side support sections. The box container further includes a cover component that is capable of engagement with the main component or the first and second side support components, such that the main component and the cover component present a fully enclosed space within the box container. The box container is erected from a knockdown configuration by folding the first and second side sections until the side sections are generally perpendicular with the base section; connecting the first and second side support components with the first and second side sections respectively; and connecting the cover component with the main component or the first and second side support components.

Abstract: A modular sign including a spacer assembly affixed to graphic panels is provided. The modular sign is movable between a knock-down configuration and an erected configuration. In the knock-down configuration, the spacer assembly lays flat on a back surface of the graphic panels. In the erected configuration, the spacer assembly is positioned behind the graphic panels so as to provide a support structure for the graphic panels while simultaneously being at least partially concealed by the graphic panels. The modular sign is moved from the knock-down configuration to the erected configuration by rotating the graphic panels up and away from a flat surface and is secured in the erected configuration by inserting a key flap into a keyhole. Once the modular sign is in the erected configuration, it can be installed onto a tube and/or another support structure, such as a register sign.

Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Abstract: A corrugated hutch display with a main section including left and right side panels opposing a back panel and a bottom panel extending from the back panel. The display includes shelf members secured to the back panel. The shelf members include bottom tabs on either side of the shelf members that are capable of being secured to the left and right side panels to secure the shelf members to the main section. The hutch display is erected from a knockdown configuration by folding the side panels until they are not coplanar with the back panel; folding the bottom panel until a portion of the back panel is aligned with the left and right side panels; folding the shelf members such that they are not coplanar with the back panel; and mating the bottom tabs of the shelf members with the left and right side panels of the main section.

Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.

Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.

Abstract: A modular sign including a spacer assembly affixed to graphic panels is provided. The modular sign is movable between a knock-down configuration and an erected configuration. In the knock-down configuration, the spacer assembly lays flat on a back surface of the graphic panels. In the erected configuration, the spacer assembly is positioned behind the graphic panels so as to provide a support structure for the graphic panels while simultaneously being at least partially concealed by the graphic panels. The modular sign is moved from the knock-down configuration to the erected configuration by rotating the graphic panels up and away from a flat surface and is secured in the erected configuration by inserting a key flap into a keyhole. Once the modular sign is in the erected configuration, it can be installed onto a tube and/or another support structure, such as a register sign.

Abstract: Method of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.